Noubar Afeyan - Moderna Insider
| 0QF Stock | EUR 36.12 1.07 3.05% |
Insider
Noubar Afeyan is Non-Executive Independent Chairman of the Board, Co-Founder of Moderna since 2012.
| Age | 60 |
| Tenure | 12 years |
| Phone | 617 714 6500 |
| Web | https://www.modernatx.com |
Noubar Afeyan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Noubar Afeyan against Moderna stock is an integral part of due diligence when investing in Moderna. Noubar Afeyan insider activity provides valuable insight into whether Moderna is net buyers or sellers over its current business cycle. Note, Moderna insiders must abide by specific rules, including filing SEC forms every time they buy or sell Moderna'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Noubar Afeyan over three months ago Disposition of 2100 shares by Noubar Afeyan of Moderna at 121.5699 subject to Rule 16b-3 | ||
Noubar Afeyan over six months ago Disposition of 7996 shares by Noubar Afeyan of Moderna at 122.0689 subject to Rule 16b-3 |
Moderna Management Efficiency
The company has return on total asset (ROA) of 0.233 % which means that it generated a profit of $0.233 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.5027 %, meaning that it generated $0.5027 on every $100 dollars invested by stockholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Herrmann | Novavax | 53 | |
| Biegie Lee | Novavax | N/A | |
| James CFA | Novavax | 57 | |
| Erika Trahan | Novavax | N/A | |
| Rachel King | Novavax | 59 | |
| Gregg Alton | Novavax | 53 | |
| Sylke Maas | BioNTech SE | N/A | |
| Gary Evans | Novavax | 61 | |
| Gregory Glenn | Novavax | 69 | |
| Margaret McGlynn | Novavax | 59 | |
| Silvia Taylor | Novavax | N/A | |
| Ben Machielse | Novavax | N/A | |
| Ozlem MD | BioNTech SE | 56 | |
| James Young | Novavax | 66 | |
| Michael McManus | Novavax | 76 | |
| Filip Dubovsky | Novavax | N/A | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
| James Ryan | BioNTech SE | N/A | |
| John III | Novavax | 57 | |
| Brian Webb | Novavax | N/A | |
| Richard Crowley | Novavax | 66 | |
Management Performance
Moderna Leadership Team
Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marcello Damiani, Chief Digital and Operational Excellence Officer | ||
| Shannon Klinger, Chief Sec | ||
| James Mock, Chief Officer | ||
| Stephane Bancel, Chief Executive Officer, Director | ||
| Lori Henderson, General Counsel, Company Secretary | ||
| Tal Zaks, Chief Medical Officer | ||
| John Reynders, Chief Officer | ||
| Paul Sagan, Non-Executive Independent Director | ||
| Lavina CFA, VP Relations | ||
| Melissa Moore, Chief Board | ||
| Francois Nader, Non-Executive Independent Director | ||
| Elizabeth Tallett, Director | ||
| Stephen Hoge, President | ||
| Noubar Afeyan, Non-Executive Independent Chairman of the Board, Co-Founder | ||
| Stephen Berenson, Non-Executive Independent Director | ||
| Stephen MD, President | ||
| Robert Langer, Non-Executive Independent Director | ||
| Tracey Franklin, Chief Human Resource Officer | ||
| Ray Jordan, Chief Corporate Affairs Officer | ||
| Jerh Collins, Chief Officer | ||
| Juan Andres, Chief Technical Operations and Quality Officer | ||
| Israel Ruiz, Non-Executive Independent Director | ||
| David Meline, Chief Financial Officer |
Moderna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | |||
| Return On Asset | 0.23 | |||
| Profit Margin | 0.43 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 69.44 B | |||
| Shares Outstanding | 385 M | |||
| Shares Owned By Insiders | 9.49 % | |||
| Shares Owned By Institutions | 68.06 % | |||
| Price To Earning | 237.44 X | |||
| Price To Book | 4.46 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Moderna Stock
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Moderna Stock please use our How to Invest in Moderna guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.